Dong Yilu, Drury Rachel, Spillane Jordan, Lodes Mark W, Penlesky Annie C, Hanson Ryan, Pezzin Liliana E, Singh Siddhartha, Nattinger Ann B
Collaborative for Healthcare Delivery Science, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
J Gen Intern Med. 2024 Oct 2. doi: 10.1007/s11606-024-08970-w.
Although several systematic reviews found that ambulatory diabetes mellitus (DM) interventions involving pharmacists generally yielded better outcomes than the ones that did not, existing studies have limitations in rigor and study design.
To examine the intention-to-treat effects of the Ambulatory Diabetes Outreach Program (ADOP) on participants' A1c values and healthcare utilization over a 52-month follow-up period.
Difference-in-differences with staggered adoption. Specifically, we employed the Callaway and Sant'Anna's "group-time average treatment effect" estimator using not-yet treated as controls adjusting for patient's age, BMI, sex, race, comorbidity, payor, and socio-economic status.
All patients with at least one ADOP treatment encounter from July 2017 to October 2021, regardless of program completion or length of exposure to the program.
ADOP, a collaborative population health program led by pharmacists and nurse specialists to provide individualized type 2 DM management and education within a large and diverse health system.
Patients' A1c values and healthcare utilization, including inpatient admission, inpatient days, and numbers of visits to the emergency department, urgent care, and primary care in recent 6 months.
ADOP participation was associated with an overall average reduction of 1.04 percentage points (95%CI - 1.12, - 0.95) in A1c level. Similar A1c reductions were also observed in the subgroups by sex and race/ethnicity. An average of 2 months were required to reach the overall average effect, which persisted over 4 years. Compared to the respective utilization levels pre-intervention, participants also had average reductions in inpatient admissions by 32.4%, inpatient days by 81.6%, visits to the emergency department by 21.6%, and primary care by 17.9%.
The results suggest that a collaborative model of pharmacist and nurse-led type 2 DM intervention was effective in improving A1c outcomes and reducing healthcare utilization in the long term.
尽管多项系统评价发现,涉及药剂师的门诊糖尿病(DM)干预措施通常比未涉及药剂师的干预措施产生更好的效果,但现有研究在严谨性和研究设计方面存在局限性。
在52个月的随访期内,研究门诊糖尿病外展项目(ADOP)对参与者糖化血红蛋白(A1c)值和医疗保健利用的意向性治疗效果。
采用交错采用的双重差分法。具体而言,我们使用卡拉韦和圣安娜的“组时间平均治疗效果”估计器,将未接受治疗的患者作为对照,并对患者的年龄、体重指数、性别、种族、合并症、付款人以及社会经济地位进行调整。
2017年7月至2021年10月期间至少接受过一次ADOP治疗的所有患者,无论是否完成该项目或参与该项目的时长。
ADOP是一项由药剂师和护士专家牵头的合作性人群健康项目,旨在一个大型多元化医疗系统内提供个性化的2型糖尿病管理和教育。
患者的A1c值和医疗保健利用情况,包括住院次数、住院天数以及最近6个月内急诊、紧急护理和初级护理的就诊次数。
参与ADOP与A1c水平总体平均降低1.04个百分点(95%置信区间-1.12,-0.95)相关。在按性别和种族/族裔划分的亚组中也观察到了类似的A1c降低情况。平均需要2个月才能达到总体平均效果,且该效果持续了4年。与干预前各自的利用水平相比,参与者的住院次数平均减少了32.4%,住院天数减少了81.6%,急诊就诊次数减少了21.6%,初级护理就诊次数减少了17.9%。
结果表明,由药剂师和护士主导的2型糖尿病干预合作模式在长期改善A1c结果和减少医疗保健利用方面是有效的。